Robot-assisted radical nephroureterectomy for upper tract urothelial carcinoma: Peri and postoperative outcomes.
Carcinoma del tracto urinario superior
Nefroureterectomía
Neoplasias urológicas
Nephroureterectomy
Procedimientos quirúrgicos robóticos
Robotic surgical procedures
Upper tract carcinoma
Urologic neoplasms
Journal
Actas urologicas espanolas
ISSN: 2173-5786
Titre abrégé: Actas Urol Esp (Engl Ed)
Pays: Spain
ID NLM: 101771154
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
19
01
2023
revised:
12
02
2023
accepted:
15
02
2023
medline:
5
9
2023
pubmed:
27
3
2023
entrez:
26
3
2023
Statut:
ppublish
Résumé
The treatment of urothelial tumours of the upper urinary tract at high risk of specific mortality is based on radical nephroureterectomy (RNU). Robotic-assisted laparoscopic radical nephroureterectomy (RARNU) is still under investigation to definitively establish the safety of this procedure in the management of urothelial tumours of the upper urinary tract. The primary objective is to evaluate the intra- and postoperative safety of RARNU and, subsequently, to evaluate the medium-term oncological results. Our study is a retrospective, mono-centric study with a collection of RARNUs conducted between 1st January 2015 and 1st October 2021. The RARNUs were performed with the assistance of the Da Vinci Si® robot, then from 2017 the Da Vinci Xi® robot. Whenever possible, the entire procedure was carried out without re-docking. Between 1st January 2015 and 1st October 2021, 29 RARNUs were carried out at our centre. Complete surgery without re-docking was possible in 80% of cases with the Da Vinci Xi® robot. One patient required conversion to open surgery due to difficult dissection. 50% of tumours were classified as T3 or T4. The 30-day complication rate was 31%. The median length of hospitalisation was 5 days. The disease-free survival at the mean survival time (27.5 months) was of 75.2%. One patient had a recurrence in the nephrectomy compartment and no patient had a peritoneal or trocar orifice recurrence. Performing RARNU for the management of tumours of the upper urinary tract appears to meet the criteria of surgical safety and those of oncological safety.
Identifiants
pubmed: 36966898
pii: S2173-5786(23)00040-9
doi: 10.1016/j.acuroe.2023.03.004
pii:
doi:
Types de publication
Journal Article
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
441-449Informations de copyright
Copyright © 2023 AEU. Published by Elsevier España, S.L.U. All rights reserved.